An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study

The Lancet Respiratory Medicine

Volumn 5, Issue 12, 2017, Pages 946-955

  Maher, Toby M ^a,b   Oballa, Eunice ^c   Simpson, Juliet K ^c   Porte, Joanne ^d,f   Habgood, Anthony ^d   Fahy, William A ^c   Flynn, Aiden ^c   Molyneaux, Philip L ^a,b   Braybrooke, Rebecca ^d,f   Divyateja, Hrushikesh ^e   Parfrey, Helen ^g   Rassl, Doris ^g   Russell, Anne Marie ^a,b   Saini, Gauri ^d,f   Renzoni, Elisabetta A ^a,b   Duggan, Anne Marie ^c   Hubbard, Richard ^d,f   Wells, Athol U ^a,b   Lukey, Pauline T ^c   Marshall, Richard P ^c   Jenkins, R Gisli ^d,f   more..

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^f NIHR NOTTINGHAM BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^g PAPWORTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19 ANTIGEN; MATRILYSIN; SURFACTANT PROTEIN D; TUMOR ANTIGEN; UNCLASSIFIED DRUG; CA 19-9 ANTIGEN;

AGE; ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDY; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX; VALIDATION STUDY; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; LUNG; METABOLISM; MORTALITY; PATHOLOGY; PREDICTIVE VALUE;

BIOMARKERS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LONGITUDINAL STUDIES; LUNG; MALE; MATRIX METALLOPROTEINASE 7; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D;

EID: 85033779884     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(17)30430-7     Document Type: Article

References (33)

1. Wolters, PJ, Collard, HR, Jones, KD, Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol 9 (2014), 157–179.
2. Ley, B, Brown, KK, Collard, HR, Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 307 (2014), L681–L691.
3. Jenkins, RG, Simpson, JK, Saini, G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 3 (2015), 462–472.
4. Saini, G, Porte, J, Weinreb, PH, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J 46 (2015), 486–494.
5. Kodama, T, Satoh, H, Ishikawa, H, Ohtsuka, M, Serum levels of CA19–9 in patients with nonmalignant respiratory diseases. J Clin Lab Anal 21 (2007), 103–106.
6. Rusanov, V, Kramer, MR, Raviv, Y, Medalion, B, Guber, A, Shitrit, D, The significance of elevated tumor markers among patients with idiopathic pulmonary fibrosis before and after lung transplantation. Chest 141 (2012), 1047–1054.
7. Dai, H, Liu, J, Liang, L, et al. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology 19 (2014), 707–713.
8. Rosas, IO, Richards, TJ, Konishi, K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med, 5, 2008, e93.
9. White, ES, Xia, M, Murray, S, et al. Plasma surfactant protein-d, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 194 (2016), 1242–1251.
10. Tzouvelekis, A, Herazo-Maya, JD, Slade, M, et al. Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis. Respirology 22 (2016), 486–493.
11. Richards, TJ, Kaminski, N, Baribaud, F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 185 (2012), 67–76.
12. Greene, KE, King, TE Jr, Kuroki, Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 19 (2002), 439–446.
13. Collard, HR, Calfee, CS, Wolters, PJ, et al. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299 (2010), L3–L7.
14. Kim, JE, Lee, KT, Lee, JK, Paik, SW, Rhee, JC, Choi, KW, Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19 (2004), 182–186.
15. Poruk, KE, Gay, DZ, Brown, K, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med 13 (2013), 340–351.
16. Das, S, Batra, SK, Understanding the unique attributes of MUC16 (CA-125): potential implications in targeted therapy. Cancer Res 75 (2015), 4669–4674.
17. Seibold, MA, Smith, RW, Urbanek, C, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One, 8, 2013, e58658.
18. Evans, CM, Fingerlin, TE, Schwarz, MI, et al. Idiopathic pulmonary fibrosis: a genetic disease that involves mucociliary dysfunction of the peripheral airways. Physiol Rev 96 (2016), 1567–1591.
19. Fingerlin, TE, Murphy, E, Zhang, W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 45 (2013), 613–620.
20. Chekmasova, AA, Rao, TD, Nikhamin, Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID-beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 16 (2010), 3594–3606.
21. Xiang, X, Feng, M, Felder, M, et al. HN125: A novel immunoadhesin targeting MUC16 with potential for cancer therapy. J Cancer 2 (2011), 280–291.
22. Argueso, P, Guzman-Aranguez, A, Mantelli, F, Cao, Z, Ricciuto, J, Panjwani, N, Association of cell surface mucins with galectin-3 contributes to the ocular surface epithelial barrier. J Biol Chem 284 (2009), 23037–23045.
23. Mackinnon, AC, Gibbons, MA, Farnworth, SL, et al. Regulation of transforming growth factor-β 1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med 185 (2012), 537–546.
24. Le Jeune, I, Gribbin, J, West, J, Smith, C, Cullinan, P, Hubbard, R, The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 101 (2007), 2534–2540.
25. Antoniou, KM, Tomassetti, S, Tsitoura, E, Vancheri, C, Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med 21 (2015), 626–633.
26. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2071–2082.
27. Reck, M, Kaiser, R, Mellemgaard, A, et al., LUME-Lung 1 Study Group. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15 (2014), 143–155.
28. McCormack, PL, Nintedanib: first global approval. Drugs 75 (2015), 129–139.
29. Vancheri, C, Common pathways in idiopathic pulmonary fibrosis and cancer. Eur Respir Rev 22 (2013), 265–272.
30. Noble, PW, Albera, C, Bradford, WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377 (2011), 1760–1769.
31. King, TE Jr, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 (2014), 2083–2092.
32. Yang, IV, Coldren, CD, Leach, SM, et al. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68 (2013), 1114–1121.
33. Maher, TM, Precision medicine in idiopathic pulmonary fibrosis. QJM 109 (2016), 585–587.